------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->
Nabi Biopharmaceuticals Appoints Leslie Hudson, Ph.D., to its Board
of Directors
- Pharmaceutical Executive Brings Scientific and Commercial
Experience to
Nabi Biopharmaceuticals' Board -
Nabi Biopharmaceuticals (Nasdaq: NABI) announced today that it has
elected Leslie Hudson, Ph.D., to its board of directors. Dr. Hudson
is currently president and chief executive officer of DOV
Pharmaceutical, Inc., and has served in several senior management
positions, including vice president of discovery research at Glaxo
Wellcome, group vice president and general manager at Phamacia Corp.
and executive vice president and chief operating officer at Repligen
Corp. With the addition of Dr. Hudson, Nabi Biopharmaceuticals'
board now totals eight members.
"Les brings a broad research background and commercial
experience in Europe and the United States that will be a tremendous
asset to our board of directors and company," stated Thomas H.
McLain, chairman, chief executive officer and president, Nabi
Biopharmaceuticals. "For more than 30 years, Les has held a number
of strategically important positions within the biotechnology and
pharmaceutical industries and in academia. We will benefit from his
expertise and experience in discovery research, product development
and commercialization at this significant point in Nabi
Biopharmaceuticals' strategic transformation."
Prior to DOV Pharmaceuticals, Dr. Hudson served as vice provost
for Strategic Initiatives at the University of Pennsylvania, where
he facilitated corporate partnerships and was responsible for
technology transfer and commercialization, corporate research and
development collaborations and regional economic development. Prior
to this position, he served in several positions at Pharmacia,
including senior vice president of research and exploratory
development, and senior vice president of emerging technology and
commercial development. He was also general manager and group vice
president of ophthalmology, where he was responsible for the
company's $1 billion ophthalmology business including the launches
of Xalatan, XalEase, Tecnis and Xalacom. Dr. Hudson also worked at
Glaxo in several senior research positions including head of cancer,
metabolic and hyperproliferative disease and vice president for
discovery research, in which he headed the company's genomics
program.
In addition to these corporate positions, Dr. Hudson has also
worked in
academia. He was a visiting scientist in the department of cell
biology at
Harvard University and head of the Department of Immunology at St.
George's
Hospital Medical School in London, where he taught for 12 years.
Dr. Hudson received his Ph.D. in immunology from the Imperial
College and
Middlesex Hospital Medical School at the University of London and
his B.A. in
zoology from the Imperial College of Science, Technology and
Medicine at the
University of London. He is also an associate of the Royal College
of Science
and has published more than 80 papers, books and articles on
immunology,
cancer and cell biology.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge
in powering
the immune system to develop and market products that fight serious
medical
conditions. We are poised to capture large, commercial
opportunities in our
core business areas: Gram-positive bacterial infections, hepatitis,
and kidney
disease (nephrology), and opportunistically in nicotine addiction.
We have
three products on the market today: PhosLo(R) (calcium acetate),
Nabi-HB(R)
[Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol
sodium
(for injection)] and a number of products in various stages of
clinical and
preclinical development. The company filed its Marketing
Authorization
Application in Europe for its product candidate, StaphVAX(R)
[Staphylococcus
aureus Polysaccharide Conjugate Vaccine], in December 2004. The
application
was accepted for review in January 2005. StaphVAX is currently in a
confirmatory Phase III clinical trial in the United States.
StaphVAX is
designed to prevent the most dangerous and prevalent strains of S.
aureus
bacterial infections. S. aureus bacteria are a major cause of
hospital-
acquired infections and are becoming increasingly resistant to
antibiotics.
The company's other products in development include Altastaph(TM)
[Staphylococcus aureus Immune Globulin Intravenous (Human)], an
antibody for
prevention and treatment of S. aureus infections, NicVAX(TM)
[Nicotine
Conjugate Vaccine], a vaccine to treat nicotine addiction, and
Civacir(TM)
[Hepatitis C Immune Globulin (Human)], an antibody for preventing
hepatitis C
virus re-infection in liver transplant patients. For additional
information
on Nabi Biopharmaceuticals, please visit our website at:
www.nabi.com .
This press release contains forward-looking statements that
reflect the
company's current expectations regarding future events. Any such
forward-
looking statements are not guarantees of future performance and
involve
significant risks and uncertainties. Actual results may differ
significantly
from those in the forward-looking statements as a result of any
number of
factors, including, but not limited to, risks relating to the
possibility that
our confirmatory Phase III clinical trial for StaphVAX or our plans
to
commercialize StaphVAX in the European Union and United States may
not be
successful; the possibility that we may not realize the value of our
acquisition of PhosLo; the company's ability to raise additional
capital on
acceptable terms; the company's dependence upon third parties to
manufacture
its products; the company's ability to utilize the full capacity of
its
manufacturing facility; the impact on sales of Nabi-HB from patient
treatment
protocols and the number of liver transplants performed in HBV-
positive
patients; reliance on a small number of customers; the future sales
growth
prospects for the company's biopharmaceutical products; and the
company's
ability to obtain regulatory approval for its products in the United
States or
abroad or to successfully develop, manufacture and market its
products. These
factors are more fully discussed in the company's Annual Report on
Form 10-K
for the fiscal year ended December 25, 2004 filed with the
Securities and
Exchange Commission.
SOURCE Nabi Biopharmaceuticals
Web Site: www.nabi.com
http://www.arizonabiotech.com/
http://www.azhttp.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/";>Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/";>Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/";>Arizona High Tech</a>
Yahoo! Groups Links
<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/
<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]
<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
